Latest Regulatory News

A1 Investments & Resources Ltd reported minimal cash flow activity for the December 2023 quarter while actively pursuing renewable energy acquisition opportunities in Japan and Australia.

Aura Energy has reported a substantial 49% increase in Ore Reserves at its flagship Tiris Uranium Project, advancing towards a Final Investment Decision in early 2025 while also benefiting from positive regulatory shifts in Sweden.

Empire Energy has successfully drilled its longest well to date, secured a $65 million financing package, and received environmental approval for its Carpentaria Pilot Project, setting the stage for first gas deliveries later in 2025.

Atturra Limited has acknowledged ongoing preliminary discussions to acquire US-based Kitepipe, a Platinum Boomi Partner, amid market speculation. While talks are incomplete, this move aligns with Atturra’s active M&A strategy.

Helios Energy has released an independent Contingent Resource Report confirming substantial recoverable oil, gas, and NGL volumes at its Presidio Project in West Texas, reinforcing its potential as a transformative asset.

EMVision Medical Devices reports strong progress in clinical trials for its emu™ Bedside Scanner, backed by robust cash reserves and strategic non-dilutive funding. The company is poised to commence pivotal FDA validation trials, marking a key step toward commercialisation.

Terramin's December 2024 quarterly report reveals major progress at its Tala Hamza Zinc Project with land acquisition and a $336 million EPC contract, while the Bird in Hand Gold Project faces a legal hurdle after the Supreme Court dismissed its mining lease application.

EBR Systems has signed a long-term lease for a 51,000 sq ft facility in Santa Clara, California, positioning itself for significant manufacturing expansion and future growth in wireless cardiac pacing technology.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Viridis Mining & Minerals has cleared major environmental and regulatory hurdles for its Colossus Rare Earth Project, securing critical local government endorsements and submitting comprehensive impact assessments that pave the way for construction in 2026.

Butn Limited has posted record quarterly revenue and platform originations for Q2 FY25, alongside sustained positive operating cash flow, signaling robust growth and strategic expansion into crypto-backed lending.

Zelira Therapeutics has received a fourth funding tranche, bringing total investment to US$3.25 million to support FDA clinical trials of its HOPE® 1 cannabinoid medicine targeting irritability in autism spectrum disorder and Phelan-McDermid Syndrome.